Skip to content

Mindfulness interventions for craving reduction in substance use disorders and behavioral addictions: systematic review and meta-analysis of randomized controlled trials

Anastasia Demina, Benjamin Petit, Vincent Meille, Benoit Trojak

BMC Neuroscience October 18, 2023 DOI: 10.1186/s12868-023-00821-4 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review and meta-analysis Randomized Peer reviewed
Sample size 1,228
Population Participants in randomized controlled trials of people with substance use disorders or behavioral addictions
Intervention Mindfulness-based interventions
Topics Addiction Meditation
Citations 20
Key findings Across 17 randomized trials (1,228 participants), mindfulness-based interventions showed an overall craving-reduction effect size of -0.70 (95% CI -1.15 to -0.26) relative to comparison conditions. The authors caution that high heterogeneity (I² = 92%), high risk of bias in most trials, and low GRADE-rated evidence quality prevented them from concluding a medium-to-large effect, and they call for better-designed research.

Abstract

Background: High-quality evidence is still required to affirm the efficacy of mindfulness-based interventions (MBIs) in craving reduction. MBIs may be particularly appropriate for this purpose given the neurobiological mechanisms of addiction with automatic behavior in response to the negative affect. In this systematic review and meta-analysis, we aimed to study the efficacy of MBIs in craving reduction and to synthetize the newly published data.

Methods: We searched four databases and three clinical trial registries for randomized controlled trials (RCTs) up to August 2023, including studies with MBIs in all types of substance use disorders or behavioral addictions. We chose as our outcome of interest the change from the baseline of craving measures at posttreatment. Standardized mean difference was used as an effect size estimator.

Results: We included 17 RCTs with 1228 participants. The overall effect size was estimated at -0.70 (95% CI -1.15, -0.26) in favor of MBIs.

Conclusion: = 92%), we were unable to conclude that there is a medium to large effect size. Overall risk of bias was high for most studies, and the GRADE approach detected a low quality of evidence. Previous clinical and fundamental research suggest that MBIs have a promising potential in addiction medicine. However, further investigation of whether MBIs effectively reduce craving is needed, and innovative solutions for resolving methodological limitations in MBI research are warranted.

Trial Registration: PROSPERO registration ID CRD42020221141.

Comparable studies

Other systematic reviews and meta-analyses on addiction, most cited first.

Study Year Design Participants
Ketamine use: a review Ketamine users 2011 Systematic review
Mindfulness Meditation for Substance Use Disorders: A Systematic Review Individuals with substance use disorders 2009 Systematic review
Mindfulness-Based Interventions for the Treatment of Substance and Behavioral Addictions: A Systematic Review 2018 Systematic review
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review 2021 Systematic review
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials Patients with psychiatric disorders, primarily alcoholism 2020 Systematic review n = 567

Citations in the library

Cited by 5

Cites 20

and 15 more in the library

Explore topics